GlassScriptPhysician profile
William Calley
NPI 1811980444
$2,698.77
in general payments reported to CMS, 2019-2025
31 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $250 · 2021: $442 · 2022: $360 · 2023: $386 · 2024: $309 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $566.56 | 2019-2025 | |
| Lilly USA, LLC | $341.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $245.71 | 2022-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $216.22 | 2019-2022 | |
| Genentech USA, INC. | $153.45 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $125.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.25 | 2021-2024 | Jardiance |
| Amarin Pharma, INC. | $102.29 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $80.58 | 2021 | |
| Abbvie INC. | $71.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $61.93 | 2023 | |
| Amgen INC. | $60.03 | 2019 | |
| Novo Nordisk INC | $59.35 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.34 | 2022 | |
| Allergan, INC. | $53.68 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $51.55 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $47.39 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.48 | 2019 | |
| Antares Pharma, INC. | $33.78 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.82 | 2022-2024 | Livalo |
| Inari Medical, INC. | $27.64 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Arbor Pharmaceuticals, INC. | $22.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.85 | 2019 | |
| Radius Health, INC. | $19.54 | 2019 | |
| Promius Pharma LLC | $17.82 | 2019 | |
| Medtronic, INC. | $16.83 | 2021 | |
| Melinta Therapeutics, LLC | $14.96 | 2019 | |
| Currax Pharmaceuticals LLC | $13.52 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.92 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.68 | 2021 | |
| Evoke Pharma, INC. | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Calley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.